Gilead Sciences received FDA approval for its newly submitted NDA on August 27, 2026, marking a significant strategic addition to its therapeutic portfolio. This regulatory milestone is expected to bolster the company's market positioning and offer substantial commercial opportunities as the approved product integrates into the competitive landscape.